Safety Physician Oncology

Seeing where an antibody actually goes: FluoSphera Licenses Debiopharm's AbYlink(TM) to pair antibody labeling with 3D tissue imaging. September 2, 2026 Antibody-drug conjugates (ADCs) have a well-known failure mode that has nothing to do with target selection. A company can identify an antibody with excellent affinity for a validated tumor antigen, attach a potent cytotoxic payload to it, and still watch the resulting conjugate underperform in the clinic, not because the biology was wrong, but because the molecule never distributed through the tumor the way the binding assay predicted it would. A new agreement between two Swiss life-sciences companies, Debiopharm and FluoSphera, is aimed squarely at that gap, the space between knowing an antibody binds its target and knowing what it does once it is actually inside a tumor. Under the license, FluoSphera has gained access to AbYlink(TM), Debiopharm's proprietary antibody conjugation technology, and will combine it with its own three-dimensional tissue-testing platform and with light-sheet microscopy from Leica Microsystems. The result, the companies say, is a single workflow that takes an antibody from labeling to quantitative imaging of its behavior in human-relevant tissue, intended for biotechnology and pharmaceutical companies developing ADCs, bispecific antibodies, and other antibody-based therapeutics. What AbYlink(TM) Actually Does AbYlink(TM) is a conjugation chemistry, not a payload or a targeting strategy. It attaches fluorescent or therapeutic cargo to the Fc region of an IgG antibody without requiring the antibody to be modified beforehand, using a regio-selective, non-enzymatic process the companies describe as completing in under an hour. Because the conjugation site sits on the Fc region rather than near the antigen-binding regions, the technology is designed to leave the antibody's original affinity for its target intact, and to produce a defined, homogeneous, batch-to-batch reproducible conjugate rather than the mixed population of species that some conventional conjugation chemistries generate. Debiopharm describes the platform as compatible with any human IgG format, including bispecific antibodies and protein-Fc fusions, and as GMP-compatible, meaning it is built to scale from an exploratory labeling experiment toward material suitable for later-stage development rather than remaining a bench-only tool. That combination, an antibody labeled without disturbing its binding surface, is what makes AbYlink(TM) useful for two otherwise separate purposes at once. The same chemistry that attaches a fluorescent tag for imaging studies can also attach a cytotoxic linker-payload to a therapeutic ADC, which is part of why Debiopharm frames the technology as compatible with most existing ADC linker chemistries, as well as with PET, SPECT, and fluorescent imaging agents. Advertisement #3 Adding a Third Dimension to Antibody Testing FluoSphera's own platform is built around three-dimensional human cell and tumor spheroid models, evaluated with multiplexed imaging and quantitative image analysis rather than the flat, two-dimensional cell culture assays that have long been standard for early antibody characterization. A conventional binding assay can establish that an antibody recognizes its target with high affinity in isolated cells; it cannot show how that same antibody distributes once it encounters the dense, three-dimensional architecture of an actual tumor, where extracellular matrix, cell packing, and heterogeneous antigen expression all shape whether a molecule penetrates to its target or is captured at the tissue margin. To visualize that distribution, FluoSphera is using the Viventis Deep light-sheet fluorescence microscope from Leica Microsystems, an optical configuration built to image deep inside intact three-dimensional samples. Applied to AbYlink(TM)-labeled antibodies within tumor spheroids*, the combination is intended to enable researchers to quantify penetration depth, distribution, and homogeneity throughout the tissue, as well as binding and target selectivity across multiple tumor cell lines and antigen-expression profiles, all within a single service rather than a series of separately commissioned studies. "Having integrated AbYlink(TM) into our platform, we are now able to offer our partners a streamlined workflow for characterizing their antibody therapeutics in human-relevant 3D models," said Clélia Bourgoint, CEO of FluoSphera. Patrick Garrouste, Drug Research & Development Executive Director at Debiopharm Research & Manufacturing, described FluoSphera's platform as an environment well suited to applying AbYlink(TM) to antibody characterization work. Andrea Boni, Market Segment Director for Human Relevant Models at Leica Microsystems, framed the collaboration around a broader trend: increasingly sophisticated 3D culture systems, he said, create a corresponding need for imaging technology capable of capturing their full complexity. Why Characterization Matters So Much for ADCs Specifically Antibody-drug conjugates occupy an unusual position in oncology drug development because they are, in effect, three drugs bound together: a targeting antibody, a linker, and a cytotoxic payload, each of which can fail in a way that is invisible if a developer only tests the finished conjugate's affinity. A linker that is too stable in circulation may never release sufficient payload within the tumor cell to be effective; one that is too labile can release payload prematurely in the bloodstream, producing systemic toxicity unrelated to the antibody's targeting. Conjugation chemistry that attaches payload molecules at random, or near the antigen-binding region, can generate a heterogeneous mixture of species within a single batch, some conjugates carrying more payload than others, some with reduced binding affinity, which complicates both manufacturing consistency and the interpretation of clinical results, since a poorly characterized conjugate makes it difficult to know which fraction of the dose is actually doing the work. Tissue penetration adds a further layer that binding assays alone cannot capture. Solid tumors are not uniformly accessible; dense stroma, irregular vasculature, and uneven antigen expression across a tumor mass mean that an antibody with excellent affinity in a dish can still fail to reach cells at the tumor core. This is part of why the field has increasingly moved toward characterizing conjugates in three-dimensional, tissue-like systems earlier in development, rather than relying solely on two-dimensional cell binding data before proceeding to animal studies. Catching a distribution problem, a stability problem, or a heterogeneity problem in an in vitro spheroid model is considerably less costly, in both time and resources, than discovering it after a candidate has advanced into preclinical toxicology or a first-in-human trial. For a modality in which the therapeutic index depends on the payload reaching tumor cells while largely sparing healthy tissue, rigorous, quantitative, tissue-level characterization is not a peripheral quality-control step; it is a substantive determinant of whether a candidate is worth advancing at all. A Service Model, Not a Therapeutic Program Neither Debiopharm nor FluoSphera is proposing a therapeutic candidate of their own through this agreement. AbYlink(TM) remains Debiopharm's proprietary conjugation technology, now licensed for use within FluoSphera's characterization service, and the arrangement is structured to let biotechnology and pharmaceutical partners bring their own antibody candidates through the combined workflow, from regio-selective labeling through 3D biological testing to quantitative imaging and data interpretation. The companies describe the current offering as available to interested partners on a target- or antibody-specific basis, including through joint proof-of-concept studies. Related Onco'Zine Coverage Hofland P. Tumor Spheroids: Bridging the Gap Between 2D Cell Assays and Solid Tumors - Onco'Zine. September 2, 2026. Online. Last accessed on September 2, 2026 References [1] Debiopharm and FluoSphera. FluoSphera Licenses Debiopharm's AbYlink(TM) Technology for 3D Antibody Characterization while Leveraging Leica Microsystems Viventis Deep Imaging Capabilities. Press release, September 1, 2026. [2] FluoSphera SA. Company overview and platform description. Online. Last accessed on September 2, 2026 [3] Debiopharm Research & Manufacturing. AbYlink(TM) technology overview. Online. Last accessed on September 2026 [4] Leica Microsystems (a Danaher company). Viventis Deep light sheet fluorescence microscope and company overview. Online. Last accessed on September 2, 2026. This article is intended for informational purposes for healthcare and life-sciences professionals. AbYlink(TM) and the FluoSphera 3D characterization workflow described here are preclinical research and development tools; they are not therapeutic products and are not subject to FDA or other regulatory approval as drugs. Feature image: (C) 2026 CH/JCO Used with permission. Advertisement #4

Swiss biotechnology company FluoSphera has licensed Debiopharm's AbYlink™ antibody conjugation technology to enhance its three-dimensional antibody characterisation platform. The agreement enables FluoSphera to offer an integrated workflow combining antibody labeling, high-throughput testing in 3D human tissue models, and quantitative imaging analysis. The platform is designed to support characterisation of antibody-drug conjugates, bispecific antibodies, and other antibody-based therapeutics. FluoSphera will use AbYlink™ to label antibody candidates, then evaluate them in 3D tumor models to assess target binding, selectivity, tissue penetration, and spatial distribution. The workflow incorporates Leica Microsystems' Viventis Deep light sheet fluorescence microscope for detailed imaging of intact tumor spheroids. FluoSphera aims to help pharmaceutical and biotechnology companies generate biologically relevant data and identify promising candidates earlier in drug development, before progressing to more resource-intensive preclinical studies.

Vancouver-based ViewsML closed an oversubscribed $4.9 million seed round to advance its virtual biomarker staining platform. Wittington Ventures led the round, with participation from new investors Mayo Clinic and Continuum Health Ventures, alongside existing backer Debiopharm. The company uses AI to generate virtual biomarker stains directly from routine H&E pathology images, eliminating the need for traditional wet-lab immunohistochemistry processes. CEO Kenneth To said the technology delivers per-cell predictions and enables spatial mapping of biomarker expression within tumour microenvironments. The platform aims to help biopharma companies generate more biomarker insights from existing tissue samples whilst conserving scarce biopsy material for downstream molecular testing. ViewsML plans to use the capital to expand its roughly 12-person team and accelerate commercialisation and clinical validation work. Mayo Clinic's participation as a new investor marks a significant endorsement, with the clinic already collaborating with ViewsML through Mayo Clinic Digital Pathology's ecosystem of AI developers.